276 related articles for article (PubMed ID: 33495919)
1. Nafamostat Mesylate is Not Effective in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis.
Matsumoto T; Okuwaki K; Imaizumi H; Kida M; Iwai T; Yamauchi H; Kaneko T; Hasegawa R; Masutani H; Tadehara M; Adachi K; Watanabe M; Kurosu T; Tamaki A; Kikuchi H; Ohno T; Koizumi W
Dig Dis Sci; 2021 Dec; 66(12):4475-4484. PubMed ID: 33495919
[TBL] [Abstract][Full Text] [Related]
2. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis.
Choi CW; Kang DH; Kim GH; Eum JS; Lee SM; Song GA; Kim DU; Kim ID; Cho M
Gastrointest Endosc; 2009 Apr; 69(4):e11-8. PubMed ID: 19327467
[TBL] [Abstract][Full Text] [Related]
3. Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: a prospective, randomized trial.
Park JY; Jeon TJ; Hwang MW; Sinn DH; Oh TH; Shin WC; Choi WC
Pancreatology; 2014; 14(4):263-7. PubMed ID: 25062874
[TBL] [Abstract][Full Text] [Related]
4. The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis.
Kim JS; Lee SH; Park N; Huh G; Chun JW; Choi JH; Cho IR; Paik WH; Ryu JK; Kim YT
BMC Gastroenterol; 2022 May; 22(1):271. PubMed ID: 35641898
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial for efficacy of nafamostat mesilate in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Ohuchida J; Chijiiwa K; Imamura N; Nagano M; Hiyoshi M
Pancreas; 2015 Apr; 44(3):415-21. PubMed ID: 25479585
[TBL] [Abstract][Full Text] [Related]
6. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?
Park KT; Kang DH; Choi CW; Cho M; Park SB; Kim HW; Kim DU; Chung CW; Yoon KT
Pancreas; 2011 Nov; 40(8):1215-9. PubMed ID: 21775918
[TBL] [Abstract][Full Text] [Related]
7. Nafamostat Reduces the Incidence of post-ERCP Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Horváth IL; Kleiner D; Nagy R; Fehérvári P; Hankó B; Hegyi P; Csupor D
Clin Pharmacol Ther; 2024 Feb; 115(2):206-212. PubMed ID: 38032816
[TBL] [Abstract][Full Text] [Related]
8. Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial.
Mansour-Ghanaei F; Joukar F; Taherzadeh Z; Sokhanvar H; Hasandokht T
World J Gastroenterol; 2016 Jun; 22(21):5114-21. PubMed ID: 27275104
[TBL] [Abstract][Full Text] [Related]
9. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials.
Xie Y; Cheng Z; Deng C; Deng M; Zhang H
Medicine (Baltimore); 2023 Oct; 102(41):e35174. PubMed ID: 37832051
[TBL] [Abstract][Full Text] [Related]
10. Pre-endoscopic retrograde cholangiopancreatography (ERCP) administration of rectal indomethacin in unselected patients to reduce post-ERCP pancreatitis: A systematic review and meta-analysis.
Garg R; Mohan BP; Krishnamoorthi R; Rustagi T
Indian J Gastroenterol; 2018 Mar; 37(2):120-126. PubMed ID: 29619673
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of nafamostat mesylate in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis of randomized controlled trials.
Narumi K; Okada T; Lin Y; Kikuchi S
Sci Rep; 2023 Dec; 13(1):23012. PubMed ID: 38155200
[TBL] [Abstract][Full Text] [Related]
12. Multicenter prospective cohort study of adverse events associated with biliary endoscopic retrograde cholangiopancreatography: Incidence of adverse events and preventive measures for post-endoscopic retrograde cholangiopancreatography pancreatitis.
Fujita K; Yazumi S; Matsumoto H; Asada M; Nebiki H; Matsumoto K; Maruo T; Takenaka M; Tomoda T; Onoyama T; Kurita A; Ueki T; Katayama T; Kawamura T; Kawamoto H;
Dig Endosc; 2022 Sep; 34(6):1198-1204. PubMed ID: 34963021
[TBL] [Abstract][Full Text] [Related]
13. Indomethacin down-regulating HMGB1 and TNF-α to prevent pancreatitis after endoscopic retrograde cholangiopancreatography.
Li L; Liu M; Zhang T; Jia Y; Zhang Y; Yuan H; Zhang G; He C
Scand J Gastroenterol; 2019 Jun; 54(6):793-799. PubMed ID: 31177924
[No Abstract] [Full Text] [Related]
14. [Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?].
Kwon YH; Kim JY; Lee SJ; Jang SY; Park HW; Yang HM; Jung MK; Jeon SW; Cho CM; Tak WY; Kweon YO; Kim SK
Korean J Gastroenterol; 2012 Mar; 59(3):232-8. PubMed ID: 22460572
[TBL] [Abstract][Full Text] [Related]
15. Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials.
Yu G; Li S; Wan R; Wang X; Hu G
Pancreas; 2015 May; 44(4):561-9. PubMed ID: 25822153
[TBL] [Abstract][Full Text] [Related]
16. [Prophylactic stents in the prevention of pancreatitis following endoscopic retrograde cholangiopancreatography].
Dubravcsik Z; Hritz I; Szepes A; Madácsy L
Orv Hetil; 2021 Jan; 162(1):31-38. PubMed ID: 33388737
[TBL] [Abstract][Full Text] [Related]
17. Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.
Hauser G; Blažević I; Salkić N; Poropat G; Giljača V; Bulić Z; Štimac D
Surg Endosc; 2017 Feb; 31(2):602-610. PubMed ID: 27317032
[TBL] [Abstract][Full Text] [Related]
18. What is impact of nonsteroidal anti-inflammatory drugs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials.
Lyu Y; Cheng Y; Wang B; Xu Y; Du W
BMC Gastroenterol; 2018 Jul; 18(1):106. PubMed ID: 29973142
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of strategies for preventing post-ERCP pancreatitis after early precut sphincterotomy for biliary access.
Ang TL; Kwek AB; Song M; Li JW; Thurairajah PH
J Dig Dis; 2016 Oct; 17(10):692-696. PubMed ID: 27556283
[TBL] [Abstract][Full Text] [Related]
20. Statin consumption and risk of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Martínez-Moneo E; Cárdenas-Jaén K; Fernández-Laso AB; Millastre-Bocos J; Torralba-Gallego A; Martín-Arriero S; Alfaro-Almajano E; García-Rayado G; de-Madaria E
Pancreatology; 2020 Jul; 20(5):801-805. PubMed ID: 32448748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
